These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29093398)

  • 21. Successful management of a possible antibiotic-related acquired factor V inhibitor: a case report and review of the literature.
    Motwani P; Howard L; Ali SS
    Acta Haematol; 2013; 129(3):182-4. PubMed ID: 23257771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paradoxic effect of multiple mild coagulation factor deficiencies on the prothrombin time and activated partial thromboplastin time.
    Burns ER; Goldberg SN; Wenz B
    Am J Clin Pathol; 1993 Aug; 100(2):94-8. PubMed ID: 8356955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired factor V inhibitor responsive to corticosteroids in a patient with double cancers.
    Endo H; Kawauchi K; Tomimatsu M; Iga D; Ogasawara T; Yasuyama M; Saito T; Otsuka K; Aiba M
    Intern Med; 2007; 46(9):621-5. PubMed ID: 17473502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A patient with hemorrhage originating from an unknown coagulation pathway inhibitor].
    Komiyama Y; Munakata M; Masuda M; Kagawa H; Fukuhara S; Takahashi H
    Rinsho Byori; 2000 Dec; 48(12):1086-92. PubMed ID: 11215416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coagulation Testing in the Core Laboratory.
    Winter WE; Flax SD; Harris NS
    Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factor V inhibitor associated with immune complex formation.
    Lazarchick J; Wolff CM; Pepkowitz SH; Kizer J; Romein LA
    Arch Pathol Lab Med; 1986 May; 110(5):448-51. PubMed ID: 3754431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Acquired factor V inhibitor].
    Yamada S; Asakura H
    Rinsho Ketsueki; 2020; 61(7):791-798. PubMed ID: 32759567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful Management of Acquired Factor V Inhibitor by Monitoring Factor V Activity, Antigen, and Inhibitor Values during Immunosuppressive Therapy.
    Mihara M; Ogawa Y; Nagasaka M; Kobayashi N; Shimizu H; Shinozawa K; Fukutake K; Inoue M; Murakami M; Handa H
    Acta Haematol; 2020; 143(5):486-490. PubMed ID: 31563916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A very potent factor V inhibitor interferes with the levels of all coagulation factors and causes a fatal hemorrhagic syndrome.
    Hoffmann C; Amiral J; Rezig S; Kerspern H; Jantzem H; Robin S; Collins A; Mornet C; Mingant F; Pan Petesch B; Ianotto JC; Lippert E; Galinat H
    Eur J Haematol; 2019 Aug; 103(2):137-139. PubMed ID: 31102471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas.
    Welsch DJ; Novotny WF; Wun TC
    Thromb Res; 1991 Oct; 64(2):213-22. PubMed ID: 1811340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolation and study of an acquired inhibitor of human coagulation factor V.
    Nesheim ME; Nichols WL; Cole TL; Houston JG; Schenk RB; Mann KG; Bowie EJ
    J Clin Invest; 1986 Feb; 77(2):405-15. PubMed ID: 3944265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Acquired coagulation disorders].
    Suzuki N
    Rinsho Ketsueki; 2020; 61(7):779-784. PubMed ID: 32759565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variability of prothrombin time and activated partial thromboplastin time in the diagnosis of increased surgical bleeding.
    Murray D; Pennell B; Olson J
    Transfusion; 1999 Jan; 39(1):56-62. PubMed ID: 9920167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coagulation factors V, VIII, and X, prothrombin time and activated partial thromboplastin time test results in thawed plasma stored at 1-6 ºC for 5 days.
    Naghadeh HT; Maghsudloo M; Tabatabaei MR
    Blood Transfus; 2011 Jan; 9(1):95-8. PubMed ID: 21235855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired Factor V Deficiency Associated with CFPM Administration.
    Yamanishi M; Nishimi Y; Usui M; Miki K; Imashuku S
    Clin Lab; 2019 Oct; 65(10):. PubMed ID: 31625361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing.
    Tripodi A; Chantarangkul V; Mannucci PM
    Br J Haematol; 2009 Oct; 147(1):77-82. PubMed ID: 19659548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acquired Factor V Inhibitors in a Patient with End-stage Renal Disease.
    Kitazawa A; Misawa H; Nagahori K; Koda R; Yoshino A; Kawamoto S; Takeda T
    Intern Med; 2016; 55(23):3505-3509. PubMed ID: 27904118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A circulating anticoagulant specific for factor V.
    Handley DA; Duncan BM
    Pathology; 1969 Oct; 1(4):265-72. PubMed ID: 5406477
    [No Abstract]   [Full Text] [Related]  

  • 39. Acquired Coagulation Factor V Inhibitor That Was Successfully Treated with Oral Corticosteroid Therapy.
    Yokota Y; Inatomi O; Nakagawa M; Kakuda K; Hiroe K; Sakai S; Osaki R; Iwasa M; Kawahara M; Kito K; Andoh A; Bamba H
    Intern Med; 2021 Aug; 60(16):2663-2666. PubMed ID: 34121013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of activated partial thromboplastin time coagulation waveform analysis for identification of patients with acquired factor VIII inhibitors.
    McGinnis E; Wong SKW; Smith TW
    Int J Lab Hematol; 2020 Aug; 42(4):411-417. PubMed ID: 32297466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.